Recent Finacing
Recent Raise
Calistoga Pharmaceuticals discovers and develops isoform-selective PI3K inhibitors, advancing CAL-101 (PI3K‑delta) in clinical evaluation for B‑cell malignancies, plus CAL-263 and additional preclinical PI3K programs for inflammatory diseases.
Focus Areas
Recent Investors
Funding round
Investors
